| Date | Title | Description |
| 16.12.2024 | Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation | ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia (“Court”) has today made orders... |
| 12.12.2024 | Results of Scheme Meeting | ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to provide the following update on the status of its proposed re-domiciliation from Austr... |
| 08.11.2024 | Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement | ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| 08.11.2024 | Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement | ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| 07.11.2024 | Bionomics to Present at the 2024 CNS Summit | ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| 04.11.2024 | Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program | ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| 07.10.2024 | Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision | ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators... |
| 03.09.2024 | Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference | ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulator... |
| 31.07.2024 | Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder | Successful End-of-Phase 2 (EoP2) meeting with U.S. Food and Drug Administration (FDA) provides a potential path to New Drug Application (NDA) submission for BNC210 for post-traumatic stress disorder (PTSD) with a single Phase 3 trial
Compan... |
| 29.07.2024 | Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 | ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| 29.07.2024 | Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 | ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| 31.05.2024 | Bionomics Limited Announces Private Placement of up to $70.0 Million | ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion ch... |
| 31.05.2024 | Bionomics Limited Announces Private Placement of up to $70.0 Million | - |
| 22.02.2024 | Bionomics to Present at the 2024 BIO CEO & Investor Conference | ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators ... |
| 05.01.2024 | Bionomics to Present at Biotech Showcase™ 2024 | The Company will provide an update on its leading asset BNC210 and their partnership strategy
ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-st... |
| 29.09.2023 | Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) | ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.
Statistically significant secondary endpoints showed improvements in depressive symptoms... |
| 03.07.2023 | Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth | Alan Fisher appointed Chair of the Board of Directors Tim Cunningham joins as Chief Financial Officer
/EIN News/ -- ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bio... |
| 30.05.2023 | Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting | /EIN News/ -- ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel... |
| 19.12.2022 | Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder | BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary Endpoint
Subjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to Placebo
BNC210 Demonstrated Favourable Saf... |
| 15.12.2022 | Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer | Experienced biotech executive to lead the next phase of growth
/EIN News/ -- ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical c... |
| 02.12.2022 | Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting | /EIN News/ -- ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed... |
| 25.10.2022 | Quarterly Activities Report for September 2022 | ADELAIDE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transfo... |
| 18.10.2022 | Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million | ADELAIDE, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$4,634,307.30 resea... |
| 04.10.2022 | Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference | ADELAIDE, Australia, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform ... |
| 31.08.2022 | Bionomics to Participate in Upcoming September Investor Conferences | ADELAIDE, Australia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the... |
| 25.08.2022 | Bionomics reports Full Year Financial Results | ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq:BNOX), today announced its financial results for the 12 months ended 30 June 2022.
Bionomics is a clinical stage biopharmaceutical company developing ... |
| 08.08.2022 | Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M | ADELAIDE, Australia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ:BNOX), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$2,085,453.17 research and development (R&am... |
| 29.07.2022 | Quarterly Activities Report for June 2022 | ADELAIDE, Australia, July 29, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a global, clinical stage biopharmaceutical company, today released its Quarterly Activities and ASX Appendix 4C Cashf... |
| 08.07.2022 | Bionomics to Participate in William Blair’s Biotech Focus Conference 2022 | ADELAIDE, Australia, July 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform ... |
| 27.06.2022 | Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference | ADELAIDE, Australia, June 27, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform ... |
| 13.06.2022 | Bionomics Investor Webinar | ADELAIDE, Australia, June 13, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO |Nasdaq: BNOX ), (Bionomics or the Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to trans... |
| 16.05.2022 | Bionomics Limited to Participate in Upcoming Investor Conferences | ADELAIDE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform t... |
| 12.01.2022 | Bionomics Limited participated in the H.C Wainwright BioConnect Conference | ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually... |
| 16.12.2021 | Bionomics Limited Announces Pricing of Initial Public Offering in the United States | ADELAIDE, Australia, Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited (Bionomics or Company), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering in the United States (the Offering) of 1,622... |
| 01.12.2021 | U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders | ADELAIDE, Australia, Dec. 1, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has grant... |
| 23.11.2021 | Bionomics Files Registration Statement for Proposed Initial Public Offering in the United States | ADELAIDE, Australia, Nov. 23, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, today announced the public filing of a registration statement on Form F-1 with t... |
| 01.11.2021 | Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study | U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study
The PREVAIL Study remains on target to initiate by end of 2021 and is expected to... |
| 20.09.2021 | Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial | Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder
Phase 2 clinical trial on target to start by end of 2021 and expected to read out topli... |
| 06.07.2021 | Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD | ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase 2b trial (the ATTUN... |
| 10.05.2021 | Bionomics BNC210 Expansion into Social Anxiety Disorder | Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder
BNC210 Phase 2b PTSD trial on target for start in mid-2021 with U.S. CRO Premier Research select... |
| 22.02.2021 | Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial | BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trialBNC210 Phase 2b PTSD trial on target for start in mid-2021 with final dose selected
ADELAIDE, Australia, Feb. 2... |
